> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Announces Priority Review Voucher Issuance
- URL: https://www.fdaweb.com/fda-announces-priority-review-voucher-issuance/
- Published: 2023-07-17T12:00:00.000Z
- Updated: 2026-09-14T18:44:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154892

*Federal Register* notice: FDA is announcing the issuance of a priority review voucher to Sarepta Therapeutics for its recently approved rare pediatric disease product application — Elevidys (delandistrogene moxeparvovec-rokl), indicated for treating ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy. Earlier this month, the company indicated it sold the voucher for $102 million to an undisclosed buyer. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-07-17/pdf/2023-15079.pdf?ref=fdaweb.com).